Towards the biological understanding of CTC: Capture technologies, definitions and potential to create metastasis

Cancers

Volumn 5, Issue 4, 2013, Pages 1619-1642

  Barradas, Ana M C ^a   Terstappen, Leon W M M ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Cancer stem cell; Circulating tumor cells; EpCAM; Filtration; Image analysis; Tumorogenesis

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; CD45 ANTIGEN; CD47 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; KI 67 ANTIGEN; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ALGORITHM; ANTIGEN EXPRESSION; AUTOMATION; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL ACTIVITY; CELL ASSAY; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CIRCULATING TUMOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; FILTRATION; HUMAN; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; METASTASIS; METASTASIS POTENTIAL; MICROFLUIDIC ANALYSIS; MOUSE MODEL; NONHUMAN; REVIEW; TUMOR INVASION; TUMOR MODEL;

EID: 84889781527     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5041619     Document Type: Review

References (109)

1. Nguyen, D.X.; Bos, P.D.; Massagué, J. Metastasis: From dissemination to organ-specific colonization. Nat. Rev. Cancer 2009. P, 274-284.
2. Cristofanilli. M.; Budd, G.T.; Ellis. M.J.; Stopeck. A.; Matera, J.; Miller. M.C.; Reuben, J.M.; Doyle, G. V; Allard, W.J.: Terstappen, L.W.M.M.; et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl. J. Med. 2004. 35L 781-791.
3. Cohen, S.J.; Punt, C.J.A.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.; Mitchell, E.; Miller, M.C.; et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 3213-3221.
4. De Bono, J.S.; Scher, H.I.; Montgomery, R.B.; Parker, C.; Miller, M.C.; Tissing, H.; Doyle, G. V; Terstappen, L.W.W.M.; Pienta, K.J.; Raghavan, D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008, 14, 6302-6309.
5. Hiltermann, T.J.N.; Pore, M.M.; van den Berg, A.; Timens, W.; Boezen, H.M.; Liesker, J.J.W.; Schouwink, J.H.; Wijnands, W.J. A; Kerner, G.S.M. A; Kruyt, F.A.E.; et al. Circulating tumor cells in small-cell lung cancer: A predictive and prognostic factor. Ann. Oncol. 2012, 23, 2937-2942.
6. Hou, J.-M.; Krebs, M.G.; Lancashire, L.; Sloane, R.; Backen, A.; Swain, R.K.; Priest, L.J.C.; Greystoke, A.; Zhou, C.; Morris, K.; et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 2012, 30, 525-532.
7. Krebs, M.G.; Sloane, R.; Priest, L.; Lancashire, L.; Hou, J.-M.; Greystoke, A.; Ward, T.H.; Ferraldeschi, R.; Hughes, A.; Clack, G.; et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol. 2011, 29, 1556-1563.
8. Budd, G.T.; Cristofanilli, M.; Ellis, M.J.; Stopeck, A.; Borden, E.; Miller, M.C.; Matera, J.; Repollet, M.; Doyle, G. V; Terstappen, L.W.M.M.; et al. Circulating tumor cells versus imaging-Predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 2006, 12, 6403-6409.
9. Allard, W.J.; Matera, J.; Miller, M.C.; Repollet, M.; Connelly, M.C.; Rao, C.; Tibbe, A.G.J.; Uhr, J.W.; Terstappen, L.W.M.M. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10, 6897-6904.
10. Coumans, F.A.W.; Ligthart, S.T.; Uhr, J.W.; Terstappen, L.W.M.M. Challenges in the enumeration and phenotyping of CTC. Clin. Cancer Res. 2012, 18, 5711-5718.
11. Hou, H.W.; Warkiani, M.E.; Khoo, B.L.; Li, Z.R.; Soo, R. A; Tan, D.S.-W.; Lim, W.-T.; Han, J.; Bhagat, A.A.S.; Lim, C.T. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci. Rep. 2013, 3, doi:10.1038/srep01259.
12. Ozkumur, E.; Shah, A.M.; Ciciliano, J.C.; Emmink, B.L.; Miyamoto, D.T.; Brachtel, E.; Yu, M.; Chen, P.; Morgan, B.; Trautwein, J.; et al. Inertial focusing for tumor antigen-dependent and-independent sorting of rare circulating tumor cells. Sci. Transl. Med. 2013, 5, doi: 10.1126/scitranslmed.3005616
13. Choi, H.; Kim, K.K.B.; Jeon, C.S.C.; Hwang, I.; Lee, S.; Kim, H.K.H.C.; Chung, T.D. A label-free DC impedance-based microcytometer for circulating rare cancer cell counting. Lab Chip 2013, 13, 970-977.
14. Coumans, F.A.W.; van Dalum, G.; Beck, M.; Terstappen, L.W.M.M. Filter characteristics influencing circulating tumor cell enrichment from whole blood. PLoS One 2013, 8, e61770.
15. Park, J.-M.; Lee, J.-Y.; Lee, J.-G.; Jeong, H.; Oh, J.-M.; Kim, Y.J.; Park, D.; Kim, M.S.; Lee, H.J.; Oh, J.H.; et al. Highly efficient assay of circulating tumor cells by selective sedimentation with a density gradient medium and microfiltration from whole blood. Anal. Chem. 2012, 84, 7400-7407.
16. Issadore, D.; Chung, J.; Shao, H.; Liong, M.; Ghazani, A. A; Castro, C.M.; Weissleder, R.; Lee, H. Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector. Sci. Transl. Med. 2012, 4, doi:10.1126/scitranslmed.3003747.
17. Kim, M.S.; Sim, T.S.; Kim, Y.J.; Kim, S.S.; Jeong, H.; Park, J.-M.; Moon, H.-S.; Kim, S.I.; Gurel, O.; Lee, S.S.; et al. SSA-MOA: A novel CTC isolation platform using selective size amplification (SSA) and a multi-obstacle architecture (MOA) filter. Lab Chip 2012, 12, 2874-2880.
18. Pantel, K.; Brakenhoff, R.H.; Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 2008, 8, 329-340.
19. Gorges, T.M.; Pantel, K. Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol. Immunother. 2013, 62, 931-939.
20. Balic, M.; Lin, H.; Williams, A. Progress in circulating tumor cell capture and analysis: Implications for cancer management. Expert Rev. Mol. Diagn. 2012, 12, 303-312.
21. Alix-Panabières, C.; Pantel, K. Circulating tumor cells: Liquid biopsy of cancer. Clin. Chem. 2013, 1, 110-118.
22. Coumans, F.; Ligthart, S.T.; Terstappen, L.W.M.M. Interpretation of changes in Circulating Tumor Cell counts. Transl. Oncol. 2012, 5, 486-491.
23. Hayes, D.F.; Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Miller, M.C.; Matera, J.; Jeffreyallard, W.; Doyle, G. V; Terstappen, L.W.W.M. Circulating Tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 2006, 12, 4218-4224.
24. Cohen, S.J.; Punt, C.J. A; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.A.; Mitchell, E.; Miller, M.C.; et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 2009, 20, 1223-1229.
25. Franken, B.; Degroot, M.R.; Mastboom, W.J.; Vermes, I.; Vanderpalen, J.; Tibbe, A.G.; Terstappen, L.W. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012, 14, doi:10.1186/bcr3333.
26. Bidard, F.-C.; Mathiot, C.; Delaloge, S.; Brain, E.; Giachetti, S.; de Cremoux, P.; Marty, M.; Pierga, J.-Y. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann. Oncol. 2010, 21, 729-733.
27. Jueckstock, J.K.; Rack, B.K.; Zwingers, T.; Hepp, P.G.M.; Schneeweiss, A.; Beckmann, M.W.; Lichtenegger, W.; Sommer, H.L.; Pantel, K.T.H.; Forstbauer, H.; et al. Prognostic relevance of circulating tumor cells (CTC) before adjuvant chemotherapy in patients with breast cancer: Results of the German SUCCESS trial. J. Clin. Oncol. 2011, 29, Abstr. 1033.
28. Lucci, A.; Hall, C.S.; Lodhi, A.K.; Bhattacharyya, A.; Anderson, A.E.; Xiao, L.; Bedrosian, I.; Kuerer, H.M.; Krishnamurthy, S. Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol. 2012, 13, 688-695.
29. Coumans, F.A.; Siesling, S.; Terstappen, L.W.M.M. Detection of cancer before distant metastasis. BMC Cancer 2013, 13, doi:10.1186/1471-2407-13-283.
30. Fischer, J.C.; Niederacher, D.; Topp, S.A.; Honisch, E.; Schumacher, S.; Schmitz, N.; Zacarias, F.L.; Vay, C.; Hoffmann, I.; Kasprowicz, N.S.; et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc. Natl. Acad. Sci. USA 2013, doi:10.1073/pnas.1313594110.
31. Hughes, A.D.; Mattison, J.; Western, L.T.; Powderly, J.D.; Greene, B.T.; King, M.R. Microtube device for selectin-mediated capture of viable circulating tumor cells from blood. Clin. Chem. 2012, 58, 846-853.
32. Lin, H.K.; Zheng, S.; Williams, A.J.; Balic, M.; Groshen, S.; Scher, H.I.; Fleisher, M.; Stadler, W.; Datar, R.H.; Tai, Y.-C.; et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin. Cancer Res. 2010, 16, 5011-5018.
33. Vona, G.; Sabile, A.; Louha, M.; Sitruk, V.; Romana, S.; Franco, D.; Pazzagli, M.; Vekemans, M.; Lacour, B.; Paterlini-bre, P. Isolation by size of epithelial tumor cells. Am. J. Pathol. 2000, 156, 57-63.
34. Nagrath, S.; Sequist, L. V; Maheswaran, S.; Bell, D.W.; Irimia, D.; Ulkus, L.; Smith, M.R.; Kwak, E.L.; Digumarthy, S.; Muzikansky, A.; et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450, 1235-1239.
35. Stott, S.L.; Hsu, C.-H.; Tsukrov, D.I.; Yu, M.; Miyamoto, D.T.; Waltman, B.A.; Rothenberg, S.M.; Shah, A.M.; Smas, M.E.; Korir, G.K.; et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. USA 2010, 107, 18392-18397.
36. Talasaz, A.H.; Powell, A.A.; Huber, D.E.; Berbee, J.G.; Roh, K.-H.; Yu, W.; Xiao, W.; Davis, M.M.; Pease, R.F.; Mindrinos, M.N.; et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc. Natl. Acad. Sci. USA 2009, 106, 3970-3975.
37. Kirby, B.J.; Jodari, M.; Loftus, M.S.; Gakhar, G.; Pratt, E.D.; Chanel-Vos, C.; Gleghorn, J.P.; Santana, S.M.; Liu, H.; Smith, J.P.; et al. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One 2012, 7, e35976.
38. Ligthart, S.T.; Coumans, F.A.W.; Attard, G.; Cassidy, A.M.; de Bono, J.S.; Terstappen, L.W.M.M. Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One 2011, 6, e27419.
39. Ligthart, S.T.; Coumans, F.A.W.; Bidard, F.-C.; Simkens, L.H.J.; Punt, C.J.A.; de Groot, M.R.; Attard, G.; de Bono, J.S.; Pierga, J.-Y.; Terstappen, L.W.M.M. Circulating tumor cells count and morphological features in breast, colorectal and prostate cancer. PLoS One 2013, 8, e67148.
40. Went, P.T.H.; Lugli, A.; Meier, S.; Bundi, M.; Mirlacher, M.; Sauter, G.; Dirnhofer, S. Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 2004, 35, 122-128.
41. Trzpis, M.; McLaughlin, P.M.J.; de Leij, L.M.F.H.; Harmsen, M.C. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am. J. Pathol. 2007, 171, 386-395.
42. Rao, C.G.; Chianese, D.; Doyle, G.V. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int. J. Oncol. 2005, 27, 49-57.
43. Gaffey, M.J.; Mills, S.E.; Swanson, P.E.; Zarbo, R.J.; Shah, A.R.; Wick, M.R. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am. J. Surg. Pathol. 1992, 16, 593-599.
44. Gastl, G.; Spizzo, G.; Obrist, P.; Dünser, M.; Mikuz, G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000, 356, 1981-1982.
45. Spizzo, G.; Fong, D.; Wurm, M.; Ensinger, C.; Obrist, P.; Hofer, C.; Mazzoleni, G.; Gastl, G.; Went, P. EpCAM expression in primary tumour tissues and metastases: An immunohistochemical analysis. J. Clin. Pathol. 2011, 64, 415-420.
46. Taube, J.H.; Herschkowitz, J.I.; Komurov, K.; Zhou, A.Y.; Gupta, S.; Yang, J.; Hartwell, K.; Onder, T.T.; Gupta, P.B.; Evans, K.W.; et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 2010, 107, 15449-15454.
47. Weinberg, R.A. Twisted epithelial-mesenchymal transition blocks senescence. Nat. Cell Biol. 2008, 10, 1021-1023.
48. Gorges, T.M.; Tinhofer, I.; Drosch, M.; Röse, L.; Zollner, T.M.; Krahn, T.; von Ahsen, O. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012, 12, doi:10.1186/1471-2407-12-178.
49. Armstrong, A.J.; Marengo, M.S.; Oltean, S.; Kemeny, G.; Bitting, R.L.; Turnbull, J.D.; Herold, C.I.; Marcom, P.K.; George, D.J.; Garcia-Blanco, M.A. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 2011, 9, 997-1007.
50. Kallergi, G.; Papadaki, M.A.; Politaki, E.; Mavroudis, D.; Georgoulias, V.; Agelaki, S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011, 13, doi:10.1186/bcr2896.
51. Raimondi, C.; Gradilone, A.; Naso, G.; Vincenzi, B.; Petracca, A.; Nicolazzo, C.; Palazzo, A.; Saltarelli, R.; Spremberg, F.; Cortesi, E.; et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 2011, 130, 449-455.
52. Mego, M.; de Giorgi, U.; Dawood, S.; Wang, X.; Valero, V.; Andreopoulou, E.; Handy, B.; Ueno, N.T.; Reuben, J.M.; Cristofanilli, M. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int. J. Cancer 2011, 129, 417-423.
53. Sieuwerts, A.M.; Kraan, J.; Bolt, J.; van der Spoel, P.; Elstrodt, F.; Schutte, M.; Martens, J.W.M.; Gratama, J.-W.; Sleijfer, S.; Foekens, J.A. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J. Natl. Cancer Inst. 2009, 101, 61-66.
54. Mostert, B.; Kraan, J.; Bolt-de Vries, J.; van der Spoel, P.; Sieuwerts, A.M.; Schutte, M.; Timmermans, A.M.; Foekens, R.; Martens, J.W.M.; Gratama, J.-W.; et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res. Treat. 2011, 127, 33-41.
55. Mostert, B.; Kraan, J.; Sieuwerts, A.M.; van der Spoel, P.; Bolt-de Vries, J.; Prager-van der Smissen, W.J.C.; Smid, M.; Timmermans, A.M.; Martens, J.W.M.; Gratama, J.W.; et al. CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett. 2012, 319, 49-55.
56. Seal, S.H. A sieve for the isolation of cancer cells and other large cells from the blood. Cancer 1964, 17, 637-642.
57. Desitter, I.; Guerrouahen, B.S.; Benali-Furet, N.; Wechsler, J.; Janne, P.A.; Kuang, Y.; Yanagita, M.; Wang, L.; Berkowitz, J.A.; Distel, R.J.; et al. A New device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 2011, 31, 427-441.
58. Adams, D.; Makarova, O.; Zhu, P.; Li, S.A.P. Isolation of circulating tumor cells by size exclusion using lithography fabricated precision microfilters. In Proceedings of the 102th Annual Meeting of the American Association for Cancer Research, Orlando, FL, USA, 2-6 April 2011; AACR: Philadelphia, PA, USA, 2011; Abstract Number 2369.
59. Coumans, F.A.W.; van Dalum, G.; Beck, M.; Terstappen, L.W.M.M. Filtration parameters influencing circulating tumor cell enrichment from whole blood. PLoS One 2013, 8, e61774.
60. Hofman, V.; Ilie, M.I.; Long, E.; Selva, E.; Bonnetaud, C.; Molina, T.; Vénissac, N.; Mouroux, J.; Vielh, P.; Hofman, P. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: Comparison of the efficacy of the CellSearch AssayTM and the isolation by size of epithelial tumor cell method. Int. J. Cancer 2011, 129, 1651-1660.
61. Krebs, M.G.; Hou, J.-M.; Sloane, R.; Lancashire, L.; Priest, L.; Nonaka, D.; Ward, T.H.; Backen, A.; Clack, G.; Hughes, A.; et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches. J. Thorac. Oncol. 2012, 7, 306-315.
62. Van Dalum, G.; Lenferink, A.; LWMM, T. Detection of EpCAM negative Circulating Tumor Cells. In Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, USA, 6-10 April 2013; AACR: Philadelphia, PA, USA, 2013; Abstract Number 1459.
63. Coumans, F.A.W.; Doggen, C.J.M.; Attard, G.; de Bono, J.S.; Terstappen, L.W.M.M. All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer. Ann. Oncol. 2010, 21, 1851-1817.
64. Larson, C.J.; Moreno, J.G.; Pienta, K.J.; Gross, S.; Repollet, M.; O'hara, S.M.; Russell, T.; Terstappen, L.W.M.M. Apoptosis of circulating tumor cells in prostate cancer patients. Cytom. Part A 2004, 62, 46-53.
65. Leers, M.P.; Kölgen, W.; Björklund, V.; Bergman, T.; Tribbick, G.; Persson, B.; Björklund, P.; Ramaekers, F.C.; Björklund, B.; Nap, M.; et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 1999, 187, 567-572.
66. Callagy, G.M.; Webber, M.J.; Pharoah, P.D.P.; Caldas, C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008, 8, doi:10.1186/1471-2407-8-153.
67. McDonnell, T.J.; Korsmeyer, S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991, 349, 254-256.
68. Smerage, J.B.; Budd, G.T.; Doyle, G. V; Brown, M.; Paoletti, C.; Muniz, M.; Miller, M.C.; Repollet, M.I.; Chianese, D.A.; Connelly, M.C.; et al. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol. Oncol. 2013, 7, 680-692.
69. Sun, Y.-F.; Xu, Y.; Yang, X.-R.; Guo, W.; Zhang, X.; Qiu, S.-J.; Shi, R.-Y.; Hu, B.; Zhou, J.; Fan, J. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013, 57, 1458-1468.
70. Méhes, G.; Witt, A.; Kubista, E.; Ambros, P. Circulating Breast cancer cells are frequently apoptotic. Am. J. Pathol. 2001, 159, 17-20.
71. Rossi, E.; Fassan, M.; Aieta, M.; Zilio, F.; Celadin, R.; Borin, M.; Grassi, A.; Troiani, L.; Basso, U.; Barile, C.; et al. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br. J. Cancer 2012, 107, 1286-1294.
72. Rossi, E.; Basso, U.; Celadin, R.; Zilio, F.; Pucciarelli, S.; Aieta, M.; Barile, C.; Sava, T.; Bonciarelli, G.; Tumolo, S.; et al. M30 neoepitope expression in epithelial cancer: Quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin. Cancer Res. 2010, 16, 5233-5243.
73. Kallergi, G.; Konstantinidis, G.; Markomanolaki, H.; Papadaki, M.A.; Mavroudis, D.; Stournaras, C.; Georgoulias, V.; Agelaki, S. Apoptotic Circulating Tumor Cells (CTCs) in early and metastatic breast cancer patients. Mol. Cancer Ther. 2013, 12, 1886-1895.
74. Fehm, T.; Becker, S.; Becker-Pergola, G.; Sotlar, K.; Gebauer, G.; Dürr-Störzer, S.; Neubauer, H.; Wallwiener, D.; Solomayer, E.-F. Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res. 2006, 8, doi:10.1186/bcr1611.
75. Ulukaya, E.; Yilmaztepe, A.; Akgoz, S.; Linder, S.; Karadag, M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007, 56, 399-404.
76. Swennenhuis, J.F.; Tibbe, A.G.J.; Levink, R.; Sipkema, R.C.J.; Terstappen, L.W.M.M. Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry 2009, 75, 520-527.
77. Campoli, M.R.; Chang, C.C.; Kageshita, T.; Wang, X.; McCarthy, J.B.; Ferrone, S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): A melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit. Rev. Immunol. 2004, 24, 267-296.
78. Weigel, M.T.; Dowsett, M. Current and emerging biomarkers in breast cancer: Prognosis and prediction. Endocr. Relat. Cancer 2010, 17, R245-R262.
79. Müller, V.; Stahmann, N.; Riethdorf, S.; Goetz, A.; Ja, F.; Pantel, K. Circulating Tumor Cells in breast cancer: Correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin. Cancer Res. 2005, 11, 3678-3685.
80. Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: An old idea-A paradigm shift. Cancer Res. 2006, 66, 1883-1890.
81. Al-Hajj, M.; Wicha, M.S.; Hernandez, A.B.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3968.
82. Ponti, D.; Costa, A.; Zaffaroni, N.; Pratesi, G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65, 5506-5511.
83. Balic, M.; Lin, H.; Young, L.; Hawes, D.; Giuliano, A.; McNamara, G.; Datar, R.H.; Cote, R.J. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 2006, 12, 5615-5621.
84. Theodoropoulos, P.A.; Polioudaki, H.; Agelaki, S.; Kallergi, G.; Saridaki, Z.; Mavroudis, D.; Georgoulias, V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010, 288, 99-106.
85. Ginestier, C.; Hur, M.; Charafe-Jauffret, E. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1, 555-567.
86. Charafe-Jauffret, E.; Ginestier, C.; Iovino, F.; Tarpin, C.; Diebel, M.; Esterni, B.; Houvenaeghel, G.; Extra, J.; Bertucci, F.; Jacquemier, J.; et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 2010, 16, 45-55.
87. Matsui, W.; Huff, C.A.; Wang, Q.; Malehorn, M.T.; Barber, J.; Tanhehco, Y.; Smith, B.D.; Civin, C.I.; Jones, R.J. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103, 2332-2336.
88. Hess, D.A.; Meyerrose, T.E.; Wirthlin, L.; Craft, T.P.; Herrbrich, P.E.; Creer, M.H.; Nolta, J.A. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004, 104, 1648-1655.
89. Pearce, D.J.; Taussig, D.; Simpson, C.; Allen, K.; Rohatiner, A.Z.; Lister, T.A.; Bonnet, D. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005, 23, 752-760.
90. Singh, S.; Hawkins, C.; Clarke, I.; Squire, J. Identification of human brain tumour initiating cells. Nature 2004, 432, 396-401.
91. Alamgeer, M.; Ganju, V.; Szczepny, A.; Russell, P.A.; Prodanovic, Z.; Kumar, B.; Wainer, Z.; Brown, T.; Schneider-Kolsky, M.; Conron, M.; et al. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax 2013, doi:10.1136/thraxjni-2012-203021.
92. Kallergi, G.; Agelaki, S.; Kalykaki, A.; Stournaras, C.; Mavroudis, D.; Georgoulias, V. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res. 2008, 10, doi:10.1186/bcr2149.
93. Korkaya, H.; Paulson, A.; Charafe-Jauffret, E.; Ginestier, C.; Brown, M.; Dutcher, J.; Clouthier, S.G.; Wicha, M.S. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009, 7, e1000121.
94. Zhou, J.; Wulfkuhle, J.; Zhang, H.; Gu, P.; Yang, Y.; Deng, J.; Margolick, J.B.; Liotta, L.A.; Petricoin, E.; Zhang, Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA 2007, 104, 16158-16163.
95. Kasimir-Bauer, S.; Hoffmann, O.; Wallwiener, D.; Kimmig, R.; Fehm, T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012, 14, doi:10.1186/bcr3099.
96. Takao, M.; Takeda, K. Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry. Cytometry 2011, 79, 107-117.
97. Bichsel, C.A.; Gobaa, S.; Kobel, S.; Secondini, C.; Thalmann, G.N.; Cecchini, M.G.; Lutolf, M.P. Diagnostic microchip to assay 3D colony-growth potential of captured circulating tumor cells. Lab Chip 2012, 12, 2313-2316.
98. Kang, J.H.; Krause, S.; Tobin, H.; Mammoto, A.; Kanapathipillai, M.; Ingber, D.E. A combined micromagnetic-microfluidic device for rapid capture and culture of rare circulating tumor cells. Lab Chip 2012, 12, 2175-2181.
99. Tumor, C.; Williams, A.; Rawal, S.; Ao, Z.; Torres-munoz, J.; Balic, M.; Zhou, M. Clinical Translation of a Novel Microfilter Technology. In Proceedings of the 2013 IEEE Point-of-Care Healthcare Technologies Meeting, Bangalore, India, 16-18 January 2013.
100. Zhang, L.; Ridgway, L.D.; Wetzel, M.D.; Ngo, J.; Yin, W.; Kumar, D.; Goodman, J.C.; Groves, M.D.; Marchetti, D. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci. Transl. Med. 2013, 5, doi:10.1126/scitranslmed.3005109.
101. Song, J.W.; Cavnar, S.P.; Walker, A.C.; Luker, K.E.; Gupta, M.; Tung, Y.-C.; Luker, G.D.; Takayama, S. Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells. PLoS One 2009, 4, e5756.
102. Byun, S.; Son, S.; Amodei, D.; Cermak, N.; Shaw, J.; Ho, J.; Hecht, V.C. Characterizing deformability and surface friction of cancer cells. Proc. Natl. Acad. Sci. USA 2013, 110, 7580-7585.
103. Jeon, J.S.; Zervantonakis, I.K.; Chung, S.; Kamm, R.D.; Charest, J.L. In vitro model of tumor cell extravasation. PLoS One 2013, 8, e56910.
104. Mak, M.; Reinhart-King, C.A.; Erickson, D. Elucidating mechanical transition effects of invading cancer cells with a subnucleus-scaled microfluidic serial dimensional modulation device. Lab Chip 2013, 13, 340-348.
105. Li, Y.; Guo, J.; Wang, C.; Fan, Z.; Liu, G.; Wang, C.; Gu, Z.; Damm, D.; Mosig, A.; Wei, X. Circulation times of prostate cancer and hepatocellular carcinoma cells by in vivo flow cytometry. Cytometry 2011, 79, 848-854.
106. Fan, Z.-C.; Yan, J.; Liu, G.-D.; Tan, X.-Y.; Weng, X.-F.; Wu, W.-Z.; Zhou, J.; Wei, X.-B. Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis. Cancer Res. 2012, 72, 2683-2691.
107. Juratli, M.A.; Sarimollaoglu, M.; Siegel, E.; Nedosekin, D.A.; Galanzha, E.; Suen, J.Y.; Zharov, V.P. Real-time monitoring of circulating tumor-cell release during tumor manipulation using in vivo photoacoustic and fluorescent flow cytometry. Head Neck 2013, doi:10.1002/hed.23439.
108. Baccelli, I.; Schneeweiss, A.; Riethdorf, S.; Stenzinger, A.; Schillert, A.; Vogel, V.; Klein, C.; Saini, M.; Bäuerle, T.; Wallwiener, M.; et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 2013, 31, doi:10.1038/nbt.2576.
109. Circulating Tumor Cells TheRapeutic APheresis (CTCTRAP). Available online: http://www.utwente.nl/tnw/ctctrap/ (accessed on 1 September 13).